You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTocilizumab
Accession NumberDB06273
TypeBiotech
GroupsApproved
DescriptionTocilizumab is a recombinant, humanized, anti-human interleukin 6 (IL-6) receptor monoclonal antibody that achieves a significant therapeutic response rate. The light chain is made up of 214 amino acids. The heavy chain is made up of 448 amino acids. The four polypeptide chains are linked intra- and inter-molecularly by disulfide bonds. FDA approved on January 8, 2010.
Protein structureDb06273
Related Articles
Protein chemical formulaC6428H9976N1720O2018S42
Protein average weight148000.0 Da
SequencesNot Available
Synonyms
Atlizumab
MRA
RoActemra®
External Identifiers
  • R-1569
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ActemraInjection, solution180 mg/mLSubcutaneousGenentech, Inc.2013-10-21Not applicableUs
ActemraSolution80 mgIntravenousHoffmann La Roche Limited2010-05-26Not applicableCanada
ActemraInjection, solution, concentrate20 mg/mLIntravenousGenentech, Inc.2010-01-08Not applicableUs
ActemraSolution200 mgIntravenousHoffmann La Roche Limited2010-05-26Not applicableCanada
ActemraInjection, solution, concentrate20 mg/mLIntravenousGenentech, Inc.2010-01-08Not applicableUs
ActemraSolution400 mgIntravenousHoffmann La Roche Limited2010-05-26Not applicableCanada
ActemraInjection, solution, concentrate20 mg/mLIntravenousGenentech, Inc.2010-01-08Not applicableUs
ActemraSolution162 mgSubcutaneousHoffmann La Roche Limited2014-05-30Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIII031V2H011
CAS number375823-41-9
Pharmacology
IndicationIndicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). It is also indicated for the treatment of active polyarticular juvenile idiopathic arthritis (PJIA) and active systemic juvenile idiopathic arthritis (SJIA) in patients 2 years of age and older.
Structured Indications
PharmacodynamicsA decrease in C-reactive protein (CRP) was noted as early as week 2. Changes in pharmacodynamic parameters were observed (i.e., decreases in rheumatoid factor, erythrocyte sedimentation rate (ESR), serum amyloid A and increases in hemoglobin) with both doses, however the greatest improvements were observed with 8 mg per kg tocilizumab. Similar pharmacodynamic changes were also observed in active polyarticular juvenile idiopathic arthritis and active systemic juvenile idiopathic arthritis patients.
Mechanism of actionInterleukin (IL)-6 plays essential roles not only in the immune response, but also in haematopoiesis and the central nervous system. Deregulated production of IL-6 has been found in chronic inflammatory autoimmune diseases, such as rheumatoid arthritis (RA), systemic onset juvenile idiopathic arthritis (soJIA), Crohn's disease (CD) and systemic lupus erythematosus (SLE). Furthermore, IL-6 activities can explain many symptoms of these diseases. More importantly, serum levels of IL-6 are correlated with disease activity. Tocilizumab binds specifically to both soluble and membrane-bound IL-6 receptors (sIL-6R and mIL-6R), and has been shown to inhibit IL-6-mediated signaling through these receptors.
TargetKindPharmacological actionActionsOrganismUniProt ID
Interleukin-6 receptor subunit alphaProteinyes
antibody
HumanP08887 details
Related Articles
AbsorptionWhen 4 mg/kg of tocilizumab was given every 4 weeks to RA patients, the pharmacokinetic parameters at steady state are as follows: AUC = 13000 ± 5800 mcg∙h/mL; Cmax = 88.3 ± 41.4 mcg/mL. Tocilizumab accumulates following repeated doses. Furthermore, an increased body weight may increase plasma levels of tocilizumab. When a dose of 8 mg/kg of tocilizumab is given to PJIA patients, the pharmacokinetic parameters are as follows: AUC = 29500 ± 8660 mcg∙h/mL; Cmax = 182 ± 37 mcg/mL. When a dose of 8 mg/kg of tocilizumab is given to SJIA patients, the pharmacokinetic parameters are as follows: AUC = 32200 ± 9960 mcg∙h/mL; Cmax = 245 ± 57.2 mcg/mL.
Volume of distribution

In rheumatoid arthritis patients the central volume of distribution was 3.5 L and the peripheral volume of distribution was 2.9 L, resulting in a volume of distribution at steady state of 6.4 L.

In pediatric patients with PJIA, the central volume of distribution was 1.98 L, the peripheral volume of distribution was 2.1 L, resulting in a volume of distribution at steady state of 4.08 L.

In pediatric patients with SJIA, the central volume of distribution was 0.94 L, the peripheral volume of distribution was 1.60 L resulting in a volume of distribution at steady state of 2.54 L.

Protein bindingNot Available
MetabolismNot Available
Route of eliminationFollowing intravenous dosing, tocilizumab undergoes biphasic elimination from the circulation.
Half lifeThe half-life of tocilizumab is concentration-dependent. The concentration-dependent apparent half-life is up to 11 days for 4 mg/kg and up to 13 days for 8 mg/kg every 4 weeks in patients with RA at steady-state. The half-life in children with PJIA is up to 16 days. The half-life in pediatric patients with SJIA is up to 23 days.
Clearance

The clearance of tocilizumab decreases with increasing dose. At the 10 mg/kg single dose in RA patients, mean clearance was 0.29 ± 0.10 mL/hr/kg. The total clearance of tocilizumab is concentration-dependent and is the sum of the linear clearance and the nonlinear clearance. At low concentrations, concentration-dependent nonlinear clearance is dominant. At high concentrations, linear clearance dominates. The estimated linear clearances for specific patient populations are as follows:
RA = 12.5 mL/h;
PJIA, pediatric patients = 5.8 mL/h;
SJIA, pediatric patients = 7.1 mL/h.

ToxicityMost common adverse reactions (incidence of at least 5%): upper respiratory tract infections, nasopharyngitis, headache, hypertension, increased ALT.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AbataceptThe risk or severity of adverse effects can be increased when Tocilizumab is combined with Abatacept.Approved
AbirateroneThe serum concentration of Abiraterone can be decreased when it is combined with Tocilizumab.Approved
AcenocoumarolThe serum concentration of Acenocoumarol can be decreased when it is combined with Tocilizumab.Approved
AcetaminophenThe serum concentration of Acetaminophen can be decreased when it is combined with Tocilizumab.Approved
AdalimumabTocilizumab may increase the immunosuppressive activities of Adalimumab.Approved
AdinazolamThe serum concentration of Adinazolam can be decreased when it is combined with Tocilizumab.Approved
AfelimomabTocilizumab may increase the immunosuppressive activities of Afelimomab.Investigational
AlbendazoleThe serum concentration of Albendazole can be decreased when it is combined with Tocilizumab.Approved, Vet Approved
AlclometasoneThe serum concentration of Alclometasone can be decreased when it is combined with Tocilizumab.Approved
AlfentanilThe serum concentration of Alfentanil can be decreased when it is combined with Tocilizumab.Approved, Illicit
AlfuzosinThe serum concentration of Alfuzosin can be decreased when it is combined with Tocilizumab.Approved, Investigational
AliskirenThe serum concentration of Aliskiren can be decreased when it is combined with Tocilizumab.Approved, Investigational
AllylestrenolThe serum concentration of Allylestrenol can be decreased when it is combined with Tocilizumab.Approved
AlmotriptanThe serum concentration of Almotriptan can be decreased when it is combined with Tocilizumab.Approved, Investigational
AlogliptinThe serum concentration of Alogliptin can be decreased when it is combined with Tocilizumab.Approved
AlosetronThe serum concentration of Alosetron can be decreased when it is combined with Tocilizumab.Approved, Withdrawn
AlprazolamThe serum concentration of Alprazolam can be decreased when it is combined with Tocilizumab.Approved, Illicit, Investigational
ALT-110The risk or severity of adverse effects can be increased when Tocilizumab is combined with ALT-110.Investigational
AmbrisentanThe serum concentration of Ambrisentan can be decreased when it is combined with Tocilizumab.Approved, Investigational
AmbroxolThe serum concentration of Ambroxol can be decreased when it is combined with Tocilizumab.Approved
AminophenazoneThe serum concentration of Aminophenazone can be decreased when it is combined with Tocilizumab.Approved, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Tocilizumab.Approved
AmiodaroneThe serum concentration of Amiodarone can be decreased when it is combined with Tocilizumab.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be decreased when it is combined with Tocilizumab.Approved
AmlodipineThe serum concentration of Amlodipine can be decreased when it is combined with Tocilizumab.Approved
AmprenavirThe serum concentration of Amprenavir can be decreased when it is combined with Tocilizumab.Approved
AnakinraThe risk or severity of adverse effects can be increased when Anakinra is combined with Tocilizumab.Approved
AntipyrineThe serum concentration of Antipyrine can be decreased when it is combined with Tocilizumab.Approved
ApixabanThe serum concentration of Apixaban can be decreased when it is combined with Tocilizumab.Approved
ApremilastThe serum concentration of Apremilast can be decreased when it is combined with Tocilizumab.Approved, Investigational
AprepitantThe serum concentration of Aprepitant can be decreased when it is combined with Tocilizumab.Approved, Investigational
ArgatrobanThe serum concentration of Argatroban can be decreased when it is combined with Tocilizumab.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Tocilizumab.Approved, Investigational
ArtemetherThe serum concentration of Artemether can be decreased when it is combined with Tocilizumab.Approved
AsenapineThe serum concentration of Asenapine can be decreased when it is combined with Tocilizumab.Approved
AstemizoleThe serum concentration of Astemizole can be decreased when it is combined with Tocilizumab.Approved, Withdrawn
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Tocilizumab.Approved, Investigational
AtorvastatinThe serum concentration of Atorvastatin can be decreased when it is combined with Tocilizumab.Approved
AvanafilThe serum concentration of Avanafil can be decreased when it is combined with Tocilizumab.Approved
AxitinibThe serum concentration of Axitinib can be decreased when it is combined with Tocilizumab.Approved, Investigational
AzelastineThe serum concentration of Azelastine can be decreased when it is combined with Tocilizumab.Approved
AzithromycinThe serum concentration of Azithromycin can be decreased when it is combined with Tocilizumab.Approved
BanoxantroneThe serum concentration of Banoxantrone can be decreased when it is combined with Tocilizumab.Investigational
BcgThe therapeutic efficacy of Bcg can be decreased when used in combination with Tocilizumab.Investigational
BedaquilineThe serum concentration of Bedaquiline can be decreased when it is combined with Tocilizumab.Approved
BelimumabThe risk or severity of adverse effects can be increased when Tocilizumab is combined with Belimumab.Approved
BenzphetamineThe serum concentration of Benzphetamine can be decreased when it is combined with Tocilizumab.Approved, Illicit
Benzyl alcoholThe serum concentration of Benzyl alcohol can be decreased when it is combined with Tocilizumab.Approved
BexaroteneThe serum concentration of Bexarotene can be decreased when it is combined with Tocilizumab.Approved, Investigational
BezafibrateThe serum concentration of Bezafibrate can be decreased when it is combined with Tocilizumab.Approved
BicalutamideThe serum concentration of Bicalutamide can be decreased when it is combined with Tocilizumab.Approved
BisoprololThe serum concentration of Bisoprolol can be decreased when it is combined with Tocilizumab.Approved
BoceprevirThe serum concentration of Boceprevir can be decreased when it is combined with Tocilizumab.Approved
BortezomibThe serum concentration of Bortezomib can be decreased when it is combined with Tocilizumab.Approved, Investigational
BosentanThe serum concentration of Bosentan can be decreased when it is combined with Tocilizumab.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Tocilizumab.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Tocilizumab.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be decreased when it is combined with Tocilizumab.Approved
BrinzolamideThe serum concentration of Brinzolamide can be decreased when it is combined with Tocilizumab.Approved
BromazepamThe serum concentration of Bromazepam can be decreased when it is combined with Tocilizumab.Approved, Illicit
BromocriptineThe serum concentration of Bromocriptine can be decreased when it is combined with Tocilizumab.Approved, Investigational
BrompheniramineThe serum concentration of Brompheniramine can be decreased when it is combined with Tocilizumab.Approved
BudesonideThe serum concentration of Budesonide can be decreased when it is combined with Tocilizumab.Approved
BupivacaineThe serum concentration of Bupivacaine can be decreased when it is combined with Tocilizumab.Approved, Investigational
BuprenorphineThe serum concentration of Buprenorphine can be decreased when it is combined with Tocilizumab.Approved, Illicit, Investigational, Vet Approved
BupropionThe serum concentration of Bupropion can be decreased when it is combined with Tocilizumab.Approved
BuspironeThe serum concentration of Buspirone can be decreased when it is combined with Tocilizumab.Approved, Investigational
BusulfanThe serum concentration of Busulfan can be decreased when it is combined with Tocilizumab.Approved, Investigational
CabazitaxelThe serum concentration of Cabazitaxel can be decreased when it is combined with Tocilizumab.Approved
CabergolineThe serum concentration of Cabergoline can be decreased when it is combined with Tocilizumab.Approved
CabozantinibThe serum concentration of Cabozantinib can be decreased when it is combined with Tocilizumab.Approved
CaffeineThe serum concentration of Caffeine can be decreased when it is combined with Tocilizumab.Approved
CalcitriolThe serum concentration of Calcitriol can be decreased when it is combined with Tocilizumab.Approved, Nutraceutical
CanagliflozinThe serum concentration of Canagliflozin can be decreased when it is combined with Tocilizumab.Approved
CarbamazepineThe serum concentration of Carbamazepine can be decreased when it is combined with Tocilizumab.Approved, Investigational
CarbinoxamineThe serum concentration of Carbinoxamine can be decreased when it is combined with Tocilizumab.Approved
CariprazineThe serum concentration of Cariprazine can be decreased when it is combined with Tocilizumab.Approved
CarvedilolThe serum concentration of Carvedilol can be decreased when it is combined with Tocilizumab.Approved, Investigational
CDX-110The risk or severity of adverse effects can be increased when Tocilizumab is combined with CDX-110.Investigational
CelecoxibThe serum concentration of Celecoxib can be decreased when it is combined with Tocilizumab.Approved, Investigational
CeliprololThe serum concentration of Celiprolol can be decreased when it is combined with Tocilizumab.Approved, Investigational
CephalexinThe serum concentration of Cephalexin can be decreased when it is combined with Tocilizumab.Approved, Vet Approved
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Tocilizumab.Withdrawn
Certolizumab pegolTocilizumab may increase the immunosuppressive activities of Certolizumab pegol.Approved
CevimelineThe serum concentration of Cevimeline can be decreased when it is combined with Tocilizumab.Approved
Chenodeoxycholic acidThe serum concentration of Chenodeoxycholic acid can be decreased when it is combined with Tocilizumab.Approved
ChlordiazepoxideThe serum concentration of Chlordiazepoxide can be decreased when it is combined with Tocilizumab.Approved, Illicit
ChloroquineThe serum concentration of Chloroquine can be decreased when it is combined with Tocilizumab.Approved, Vet Approved
ChlorphenamineThe serum concentration of Chlorphenamine can be decreased when it is combined with Tocilizumab.Approved
ChlorpromazineThe serum concentration of Chlorpromazine can be decreased when it is combined with Tocilizumab.Approved, Vet Approved
ChlorzoxazoneThe serum concentration of Chlorzoxazone can be decreased when it is combined with Tocilizumab.Approved
CholecalciferolThe serum concentration of Cholecalciferol can be decreased when it is combined with Tocilizumab.Approved, Nutraceutical
CiclesonideThe serum concentration of Ciclesonide can be decreased when it is combined with Tocilizumab.Approved, Investigational
CilostazolThe serum concentration of Cilostazol can be decreased when it is combined with Tocilizumab.Approved
CinacalcetThe serum concentration of Cinacalcet can be decreased when it is combined with Tocilizumab.Approved
CisaprideThe serum concentration of Cisapride can be decreased when it is combined with Tocilizumab.Approved, Investigational, Withdrawn
CitalopramThe serum concentration of Citalopram can be decreased when it is combined with Tocilizumab.Approved
ClarithromycinThe serum concentration of Clarithromycin can be decreased when it is combined with Tocilizumab.Approved
ClindamycinThe serum concentration of Clindamycin can be decreased when it is combined with Tocilizumab.Approved, Vet Approved
ClobazamThe serum concentration of Clobazam can be decreased when it is combined with Tocilizumab.Approved, Illicit
ClofazimineThe serum concentration of Clofazimine can be decreased when it is combined with Tocilizumab.Approved, Investigational
ClofibrateThe serum concentration of Clofibrate can be decreased when it is combined with Tocilizumab.Approved
clomethiazoleThe serum concentration of clomethiazole can be decreased when it is combined with Tocilizumab.Investigational
ClomipramineThe serum concentration of Clomipramine can be decreased when it is combined with Tocilizumab.Approved, Vet Approved
ClonazepamThe serum concentration of Clonazepam can be decreased when it is combined with Tocilizumab.Approved, Illicit
ClonidineThe serum concentration of Clonidine can be decreased when it is combined with Tocilizumab.Approved
ClopidogrelThe serum concentration of Clopidogrel can be decreased when it is combined with Tocilizumab.Approved, Nutraceutical
ClorazepateThe serum concentration of Clorazepate can be decreased when it is combined with Tocilizumab.Approved, Illicit
ClotiazepamThe serum concentration of Clotiazepam can be decreased when it is combined with Tocilizumab.Approved, Illicit
ClozapineThe serum concentration of Clozapine can be decreased when it is combined with Tocilizumab.Approved
CocaineThe serum concentration of Cocaine can be decreased when it is combined with Tocilizumab.Approved, Illicit
CodeineThe serum concentration of Codeine can be decreased when it is combined with Tocilizumab.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be decreased when it is combined with Tocilizumab.Approved
ConivaptanThe serum concentration of Conivaptan can be decreased when it is combined with Tocilizumab.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Tocilizumab.Approved
Cortisone acetateThe serum concentration of Cortisone acetate can be decreased when it is combined with Tocilizumab.Approved
CrizotinibThe serum concentration of Crizotinib can be decreased when it is combined with Tocilizumab.Approved
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Tocilizumab.Approved
CyclophosphamideThe serum concentration of Cyclophosphamide can be decreased when it is combined with Tocilizumab.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be decreased when it is combined with Tocilizumab.Approved, Investigational, Vet Approved
CytarabineThe serum concentration of Cytarabine can be decreased when it is combined with Tocilizumab.Approved, Investigational
DabrafenibThe serum concentration of Dabrafenib can be decreased when it is combined with Tocilizumab.Approved
DaclatasvirThe serum concentration of Daclatasvir can be decreased when it is combined with Tocilizumab.Approved
DantroleneThe serum concentration of Dantrolene can be decreased when it is combined with Tocilizumab.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be decreased when it is combined with Tocilizumab.Approved
DapsoneThe serum concentration of Dapsone can be decreased when it is combined with Tocilizumab.Approved, Investigational
DarifenacinThe serum concentration of Darifenacin can be decreased when it is combined with Tocilizumab.Approved, Investigational
DarunavirThe serum concentration of Darunavir can be decreased when it is combined with Tocilizumab.Approved
DasabuvirThe serum concentration of Dasabuvir can be decreased when it is combined with Tocilizumab.Approved
DasatinibThe serum concentration of Dasatinib can be decreased when it is combined with Tocilizumab.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be decreased when it is combined with Tocilizumab.Approved
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Tocilizumab.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Tocilizumab.Approved
DesvenlafaxineThe serum concentration of Desvenlafaxine can be decreased when it is combined with Tocilizumab.Approved
DexamethasoneThe serum concentration of Dexamethasone can be decreased when it is combined with Tocilizumab.Approved, Investigational, Vet Approved
DextromethorphanThe serum concentration of Dextromethorphan can be decreased when it is combined with Tocilizumab.Approved
DextropropoxypheneThe serum concentration of Dextropropoxyphene can be decreased when it is combined with Tocilizumab.Approved, Illicit, Withdrawn
DiazepamThe serum concentration of Diazepam can be decreased when it is combined with Tocilizumab.Approved, Illicit, Vet Approved
DiclofenacThe serum concentration of Diclofenac can be decreased when it is combined with Tocilizumab.Approved, Vet Approved
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Tocilizumab.Approved
DigoxinThe serum concentration of Digoxin can be decreased when it is combined with Tocilizumab.Approved
DihydrocodeineThe serum concentration of Dihydrocodeine can be decreased when it is combined with Tocilizumab.Approved, Illicit
DihydroergotamineThe serum concentration of Dihydroergotamine can be decreased when it is combined with Tocilizumab.Approved
DiltiazemThe serum concentration of Diltiazem can be decreased when it is combined with Tocilizumab.Approved
DisopyramideThe serum concentration of Disopyramide can be decreased when it is combined with Tocilizumab.Approved
DisulfiramThe serum concentration of Disulfiram can be decreased when it is combined with Tocilizumab.Approved
DocetaxelThe serum concentration of Docetaxel can be decreased when it is combined with Tocilizumab.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be decreased when it is combined with Tocilizumab.Approved
DolasetronThe serum concentration of Dolasetron can be decreased when it is combined with Tocilizumab.Approved
DomperidoneThe serum concentration of Domperidone can be decreased when it is combined with Tocilizumab.Approved, Investigational, Vet Approved
DonepezilThe serum concentration of Donepezil can be decreased when it is combined with Tocilizumab.Approved
DorzolamideThe serum concentration of Dorzolamide can be decreased when it is combined with Tocilizumab.Approved
DoxepinThe serum concentration of Doxepin can be decreased when it is combined with Tocilizumab.Approved
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Tocilizumab.Approved, Investigational
DronabinolThe serum concentration of Dronabinol can be decreased when it is combined with Tocilizumab.Approved, Illicit
DronedaroneThe serum concentration of Dronedarone can be decreased when it is combined with Tocilizumab.Approved
DutasterideThe serum concentration of Dutasteride can be decreased when it is combined with Tocilizumab.Approved, Investigational
EfavirenzThe serum concentration of Efavirenz can be decreased when it is combined with Tocilizumab.Approved, Investigational
EletriptanThe serum concentration of Eletriptan can be decreased when it is combined with Tocilizumab.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be decreased when it is combined with Tocilizumab.Approved
ElvitegravirThe serum concentration of Elvitegravir can be decreased when it is combined with Tocilizumab.Approved
EnalaprilThe serum concentration of Enalapril can be decreased when it is combined with Tocilizumab.Approved, Vet Approved
EnzalutamideThe serum concentration of Enzalutamide can be decreased when it is combined with Tocilizumab.Approved
EpinastineThe serum concentration of Epinastine can be decreased when it is combined with Tocilizumab.Approved, Investigational
EplerenoneThe serum concentration of Eplerenone can be decreased when it is combined with Tocilizumab.Approved
ErgocalciferolThe serum concentration of Ergocalciferol can be decreased when it is combined with Tocilizumab.Approved, Nutraceutical
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Tocilizumab.Approved
ErgonovineThe serum concentration of Ergonovine can be decreased when it is combined with Tocilizumab.Approved
ErgotamineThe serum concentration of Ergotamine can be decreased when it is combined with Tocilizumab.Approved
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Tocilizumab.Approved, Investigational
ErythromycinThe serum concentration of Erythromycin can be decreased when it is combined with Tocilizumab.Approved, Vet Approved
EscitalopramThe serum concentration of Escitalopram can be decreased when it is combined with Tocilizumab.Approved, Investigational
EsomeprazoleThe serum concentration of Esomeprazole can be decreased when it is combined with Tocilizumab.Approved, Investigational
EstazolamThe serum concentration of Estazolam can be decreased when it is combined with Tocilizumab.Approved, Illicit
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Tocilizumab.Approved, Investigational, Vet Approved
Estradiol valerate/DienogestThe serum concentration of Estradiol valerate/Dienogest can be decreased when it is combined with Tocilizumab.Approved
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Tocilizumab.Approved
EstroneThe serum concentration of Estrone can be decreased when it is combined with Tocilizumab.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Tocilizumab.Approved
EszopicloneThe serum concentration of Eszopiclone can be decreased when it is combined with Tocilizumab.Approved
EtanerceptTocilizumab may increase the immunosuppressive activities of Etanercept.Approved, Investigational
EthanolThe serum concentration of Ethanol can be decreased when it is combined with Tocilizumab.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Tocilizumab.Approved
EthosuximideThe serum concentration of Ethosuximide can be decreased when it is combined with Tocilizumab.Approved
EthylmorphineThe serum concentration of Ethylmorphine can be decreased when it is combined with Tocilizumab.Approved, Illicit
EtonogestrelThe serum concentration of Etonogestrel can be decreased when it is combined with Tocilizumab.Approved, Investigational
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Tocilizumab.Approved
EtoricoxibThe serum concentration of Etoricoxib can be decreased when it is combined with Tocilizumab.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Tocilizumab.Approved
EverolimusThe serum concentration of Everolimus can be decreased when it is combined with Tocilizumab.Approved
ExemestaneThe serum concentration of Exemestane can be decreased when it is combined with Tocilizumab.Approved, Investigational
FamciclovirThe serum concentration of Famciclovir can be decreased when it is combined with Tocilizumab.Approved
FelbamateThe serum concentration of Felbamate can be decreased when it is combined with Tocilizumab.Approved
FelodipineThe serum concentration of Felodipine can be decreased when it is combined with Tocilizumab.Approved, Investigational
FenofibrateThe serum concentration of Fenofibrate can be decreased when it is combined with Tocilizumab.Approved
FentanylThe serum concentration of Fentanyl can be decreased when it is combined with Tocilizumab.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of Fesoterodine can be decreased when it is combined with Tocilizumab.Approved
FinasterideThe serum concentration of Finasteride can be decreased when it is combined with Tocilizumab.Approved
FingolimodTocilizumab may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FlibanserinThe serum concentration of Flibanserin can be decreased when it is combined with Tocilizumab.Approved
FlunisolideThe serum concentration of Flunisolide can be decreased when it is combined with Tocilizumab.Approved, Investigational
FlunitrazepamThe serum concentration of Flunitrazepam can be decreased when it is combined with Tocilizumab.Approved, Illicit
FluorometholoneThe serum concentration of Fluorometholone can be decreased when it is combined with Tocilizumab.Approved
FluoxetineThe serum concentration of Fluoxetine can be decreased when it is combined with Tocilizumab.Approved, Vet Approved
FlurazepamThe serum concentration of Flurazepam can be decreased when it is combined with Tocilizumab.Approved, Illicit
FlutamideThe serum concentration of Flutamide can be decreased when it is combined with Tocilizumab.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be decreased when it is combined with Tocilizumab.Approved
Fluticasone PropionateThe serum concentration of Fluticasone Propionate can be decreased when it is combined with Tocilizumab.Approved
FluvastatinThe serum concentration of Fluvastatin can be decreased when it is combined with Tocilizumab.Approved
FosamprenavirThe serum concentration of Fosamprenavir can be decreased when it is combined with Tocilizumab.Approved
FulvestrantThe serum concentration of Fulvestrant can be decreased when it is combined with Tocilizumab.Approved, Investigational
G17DTThe risk or severity of adverse effects can be increased when Tocilizumab is combined with G17DT.Investigational
GalantamineThe serum concentration of Galantamine can be decreased when it is combined with Tocilizumab.Approved
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Tocilizumab.Approved, Investigational
GemfibrozilThe serum concentration of Gemfibrozil can be decreased when it is combined with Tocilizumab.Approved
GI-5005The risk or severity of adverse effects can be increased when Tocilizumab is combined with GI-5005.Investigational
GlipizideThe serum concentration of Glipizide can be decreased when it is combined with Tocilizumab.Approved
GlyburideThe serum concentration of Glyburide can be decreased when it is combined with Tocilizumab.Approved
GolimumabTocilizumab may increase the immunosuppressive activities of Golimumab.Approved
GranisetronThe serum concentration of Granisetron can be decreased when it is combined with Tocilizumab.Approved, Investigational
GrepafloxacinThe serum concentration of Grepafloxacin can be decreased when it is combined with Tocilizumab.Withdrawn
GuanfacineThe serum concentration of Guanfacine can be decreased when it is combined with Tocilizumab.Approved, Investigational
HalofantrineThe serum concentration of Halofantrine can be decreased when it is combined with Tocilizumab.Approved
HaloperidolThe serum concentration of Haloperidol can be decreased when it is combined with Tocilizumab.Approved
HalothaneThe serum concentration of Halothane can be decreased when it is combined with Tocilizumab.Approved, Vet Approved
HexobarbitalThe serum concentration of Hexobarbital can be decreased when it is combined with Tocilizumab.Approved
Histamine PhosphateThe serum concentration of Histamine Phosphate can be decreased when it is combined with Tocilizumab.Approved
HydrocodoneThe serum concentration of Hydrocodone can be decreased when it is combined with Tocilizumab.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be decreased when it is combined with Tocilizumab.Approved, Vet Approved
HydromorphoneThe serum concentration of Hydromorphone can be decreased when it is combined with Tocilizumab.Approved, Illicit
Hydroxyprogesterone caproateThe serum concentration of Hydroxyprogesterone caproate can be decreased when it is combined with Tocilizumab.Approved
IbrutinibThe serum concentration of Ibrutinib can be decreased when it is combined with Tocilizumab.Approved
IfosfamideThe serum concentration of Ifosfamide can be decreased when it is combined with Tocilizumab.Approved
IloperidoneThe serum concentration of Iloperidone can be decreased when it is combined with Tocilizumab.Approved
ImatinibThe serum concentration of Imatinib can be decreased when it is combined with Tocilizumab.Approved
ImipramineThe serum concentration of Imipramine can be decreased when it is combined with Tocilizumab.Approved
ImiquimodThe serum concentration of Imiquimod can be decreased when it is combined with Tocilizumab.Approved, Investigational
IndacaterolThe serum concentration of Indacaterol can be decreased when it is combined with Tocilizumab.Approved
IndapamideThe serum concentration of Indapamide can be decreased when it is combined with Tocilizumab.Approved
IndinavirThe serum concentration of Indinavir can be decreased when it is combined with Tocilizumab.Approved
InfliximabTocilizumab may increase the immunosuppressive activities of Infliximab.Approved
INGN 201The risk or severity of adverse effects can be increased when Tocilizumab is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Tocilizumab is combined with INGN 225.Investigational
Ipratropium bromideThe serum concentration of Ipratropium bromide can be decreased when it is combined with Tocilizumab.Approved
IrinotecanThe serum concentration of Irinotecan can be decreased when it is combined with Tocilizumab.Approved, Investigational
IsavuconazoniumThe serum concentration of Isavuconazonium can be decreased when it is combined with Tocilizumab.Approved, Investigational
Isosorbide DinitrateThe serum concentration of Isosorbide Dinitrate can be decreased when it is combined with Tocilizumab.Approved
Isosorbide MononitrateThe serum concentration of Isosorbide Mononitrate can be decreased when it is combined with Tocilizumab.Approved
IsradipineThe serum concentration of Isradipine can be decreased when it is combined with Tocilizumab.Approved
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Tocilizumab.Approved, Investigational
IvabradineThe serum concentration of Ivabradine can be decreased when it is combined with Tocilizumab.Approved
IvacaftorThe serum concentration of Ivacaftor can be decreased when it is combined with Tocilizumab.Approved
IvermectinThe serum concentration of Ivermectin can be decreased when it is combined with Tocilizumab.Approved, Vet Approved
IxabepiloneThe serum concentration of Ixabepilone can be decreased when it is combined with Tocilizumab.Approved, Investigational
IxazomibThe serum concentration of Ixazomib can be decreased when it is combined with Tocilizumab.Approved
KetamineThe serum concentration of Ketamine can be decreased when it is combined with Tocilizumab.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be decreased when it is combined with Tocilizumab.Approved
KetobemidoneThe serum concentration of Ketobemidone can be decreased when it is combined with Tocilizumab.Approved
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Tocilizumab.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be decreased when it is combined with Tocilizumab.Approved, Investigational
LapatinibThe serum concentration of Lapatinib can be decreased when it is combined with Tocilizumab.Approved, Investigational
LaquinimodThe serum concentration of Laquinimod can be decreased when it is combined with Tocilizumab.Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Tocilizumab is combined with Leflunomide.Approved, Investigational
LenvatinibThe serum concentration of Lenvatinib can be decreased when it is combined with Tocilizumab.Approved
LercanidipineThe serum concentration of Lercanidipine can be decreased when it is combined with Tocilizumab.Approved, Investigational
LetrozoleThe serum concentration of Letrozole can be decreased when it is combined with Tocilizumab.Approved, Investigational
LevobupivacaineThe serum concentration of Levobupivacaine can be decreased when it is combined with Tocilizumab.Approved
LevocetirizineThe serum concentration of Levocetirizine can be decreased when it is combined with Tocilizumab.Approved
Levomethadyl AcetateThe serum concentration of Levomethadyl Acetate can be decreased when it is combined with Tocilizumab.Approved
LevomilnacipranThe serum concentration of Levomilnacipran can be decreased when it is combined with Tocilizumab.Approved
LevonorgestrelThe serum concentration of Levonorgestrel can be decreased when it is combined with Tocilizumab.Approved, Investigational
LevothyroxineThe serum concentration of Levothyroxine can be decreased when it is combined with Tocilizumab.Approved
LidocaineThe serum concentration of Lidocaine can be decreased when it is combined with Tocilizumab.Approved, Vet Approved
LisurideThe serum concentration of Lisuride can be decreased when it is combined with Tocilizumab.Approved
LomitapideThe serum concentration of Lomitapide can be decreased when it is combined with Tocilizumab.Approved
LoperamideThe serum concentration of Loperamide can be decreased when it is combined with Tocilizumab.Approved
LopinavirThe serum concentration of Lopinavir can be decreased when it is combined with Tocilizumab.Approved
LoratadineThe serum concentration of Loratadine can be decreased when it is combined with Tocilizumab.Approved
LorcaserinThe serum concentration of Lorcaserin can be decreased when it is combined with Tocilizumab.Approved
LosartanThe serum concentration of Losartan can be decreased when it is combined with Tocilizumab.Approved
LovastatinThe serum concentration of Lovastatin can be decreased when it is combined with Tocilizumab.Approved, Investigational
LumefantrineThe serum concentration of Lumefantrine can be decreased when it is combined with Tocilizumab.Approved
LurasidoneThe serum concentration of Lurasidone can be decreased when it is combined with Tocilizumab.Approved
MacitentanThe serum concentration of Macitentan can be decreased when it is combined with Tocilizumab.Approved
MaravirocThe serum concentration of Maraviroc can be decreased when it is combined with Tocilizumab.Approved, Investigational
MebendazoleThe serum concentration of Mebendazole can be decreased when it is combined with Tocilizumab.Approved, Vet Approved
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Tocilizumab.Approved, Investigational
MefloquineThe serum concentration of Mefloquine can be decreased when it is combined with Tocilizumab.Approved
MeloxicamThe serum concentration of Meloxicam can be decreased when it is combined with Tocilizumab.Approved, Vet Approved
MethadoneThe serum concentration of Methadone can be decreased when it is combined with Tocilizumab.Approved
MethaqualoneThe serum concentration of Methaqualone can be decreased when it is combined with Tocilizumab.Illicit, Withdrawn
MethoxsalenThe serum concentration of Methoxsalen can be decreased when it is combined with Tocilizumab.Approved
MethoxyfluraneThe serum concentration of Methoxyflurane can be decreased when it is combined with Tocilizumab.Approved, Vet Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be decreased when it is combined with Tocilizumab.Approved, Vet Approved
MethyltestosteroneThe serum concentration of Methyltestosterone can be decreased when it is combined with Tocilizumab.Approved
MetronidazoleThe serum concentration of Metronidazole can be decreased when it is combined with Tocilizumab.Approved
MexiletineThe serum concentration of Mexiletine can be decreased when it is combined with Tocilizumab.Approved
MianserinThe serum concentration of Mianserin can be decreased when it is combined with Tocilizumab.Approved
MibefradilThe serum concentration of Mibefradil can be decreased when it is combined with Tocilizumab.Withdrawn
MiconazoleThe serum concentration of Miconazole can be decreased when it is combined with Tocilizumab.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Midazolam can be decreased when it is combined with Tocilizumab.Approved, Illicit
MifepristoneThe serum concentration of Mifepristone can be decreased when it is combined with Tocilizumab.Approved, Investigational
MirabegronThe serum concentration of Mirabegron can be decreased when it is combined with Tocilizumab.Approved
MirtazapineThe serum concentration of Mirtazapine can be decreased when it is combined with Tocilizumab.Approved
ModafinilThe serum concentration of Modafinil can be decreased when it is combined with Tocilizumab.Approved, Investigational
MontelukastThe serum concentration of Montelukast can be decreased when it is combined with Tocilizumab.Approved
MorphineThe serum concentration of Morphine can be decreased when it is combined with Tocilizumab.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Tocilizumab.Approved, Investigational
NaloxegolThe serum concentration of Naloxegol can be decreased when it is combined with Tocilizumab.Approved
NaloxoneThe serum concentration of Naloxone can be decreased when it is combined with Tocilizumab.Approved, Vet Approved
NatalizumabThe risk or severity of adverse effects can be increased when Tocilizumab is combined with Natalizumab.Approved, Investigational
NateglinideThe serum concentration of Nateglinide can be decreased when it is combined with Tocilizumab.Approved, Investigational
NefazodoneThe serum concentration of Nefazodone can be decreased when it is combined with Tocilizumab.Approved, Withdrawn
NelfinavirThe serum concentration of Nelfinavir can be decreased when it is combined with Tocilizumab.Approved
NevirapineThe serum concentration of Nevirapine can be decreased when it is combined with Tocilizumab.Approved
NicardipineThe serum concentration of Nicardipine can be decreased when it is combined with Tocilizumab.Approved
NicotineThe serum concentration of Nicotine can be decreased when it is combined with Tocilizumab.Approved
NifedipineThe serum concentration of Nifedipine can be decreased when it is combined with Tocilizumab.Approved
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Tocilizumab.Approved, Investigational
NilvadipineThe serum concentration of Nilvadipine can be decreased when it is combined with Tocilizumab.Approved
NimodipineThe serum concentration of Nimodipine can be decreased when it is combined with Tocilizumab.Approved
NisoldipineThe serum concentration of Nisoldipine can be decreased when it is combined with Tocilizumab.Approved
NitrazepamThe serum concentration of Nitrazepam can be decreased when it is combined with Tocilizumab.Approved
NitrendipineThe serum concentration of Nitrendipine can be decreased when it is combined with Tocilizumab.Approved
NorethisteroneThe serum concentration of Norethisterone can be decreased when it is combined with Tocilizumab.Approved
NorgestrelThe serum concentration of Norgestrel can be decreased when it is combined with Tocilizumab.Approved
NortriptylineThe serum concentration of Nortriptyline can be decreased when it is combined with Tocilizumab.Approved
OlaparibThe serum concentration of Olaparib can be decreased when it is combined with Tocilizumab.Approved
OlopatadineThe serum concentration of Olopatadine can be decreased when it is combined with Tocilizumab.Approved
OmeprazoleThe serum concentration of Omeprazole can be decreased when it is combined with Tocilizumab.Approved, Investigational, Vet Approved
OndansetronThe serum concentration of Ondansetron can be decreased when it is combined with Tocilizumab.Approved
OrphenadrineThe serum concentration of Orphenadrine can be decreased when it is combined with Tocilizumab.Approved
OspemifeneThe serum concentration of Ospemifene can be decreased when it is combined with Tocilizumab.Approved
OxazepamThe serum concentration of Oxazepam can be decreased when it is combined with Tocilizumab.Approved
OxybutyninThe serum concentration of Oxybutynin can be decreased when it is combined with Tocilizumab.Approved, Investigational
OxycodoneThe serum concentration of Oxycodone can be decreased when it is combined with Tocilizumab.Approved, Illicit, Investigational
OxymorphoneThe serum concentration of Oxymorphone can be decreased when it is combined with Tocilizumab.Approved, Investigational, Vet Approved
PaclitaxelThe serum concentration of Paclitaxel can be decreased when it is combined with Tocilizumab.Approved, Vet Approved
PalbociclibThe serum concentration of Palbociclib can be decreased when it is combined with Tocilizumab.Approved
PalonosetronThe serum concentration of Palonosetron can be decreased when it is combined with Tocilizumab.Approved, Investigational
PanobinostatThe serum concentration of Panobinostat can be decreased when it is combined with Tocilizumab.Approved, Investigational
PantoprazoleThe serum concentration of Pantoprazole can be decreased when it is combined with Tocilizumab.Approved
ParamethadioneThe serum concentration of Paramethadione can be decreased when it is combined with Tocilizumab.Approved
ParamethasoneThe serum concentration of Paramethasone can be decreased when it is combined with Tocilizumab.Approved
ParecoxibThe serum concentration of Parecoxib can be decreased when it is combined with Tocilizumab.Approved
ParicalcitolThe serum concentration of Paricalcitol can be decreased when it is combined with Tocilizumab.Approved, Investigational
ParitaprevirThe serum concentration of Paritaprevir can be decreased when it is combined with Tocilizumab.Approved
PazopanibThe serum concentration of Pazopanib can be decreased when it is combined with Tocilizumab.Approved
PentamidineThe serum concentration of Pentamidine can be decreased when it is combined with Tocilizumab.Approved
PerampanelThe serum concentration of Perampanel can be decreased when it is combined with Tocilizumab.Approved
PergolideThe serum concentration of Pergolide can be decreased when it is combined with Tocilizumab.Approved, Vet Approved, Withdrawn
PerhexilineThe serum concentration of Perhexiline can be decreased when it is combined with Tocilizumab.Approved
PermethrinThe serum concentration of Permethrin can be decreased when it is combined with Tocilizumab.Approved, Investigational
PerphenazineThe serum concentration of Perphenazine can be decreased when it is combined with Tocilizumab.Approved
PethidineThe serum concentration of Pethidine can be decreased when it is combined with Tocilizumab.Approved
PhenacetinThe serum concentration of Phenacetin can be decreased when it is combined with Tocilizumab.Withdrawn
PhenoxybenzamineThe serum concentration of Phenoxybenzamine can be decreased when it is combined with Tocilizumab.Approved
PhenprocoumonThe serum concentration of Phenprocoumon can be decreased when it is combined with Tocilizumab.Approved
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with Tocilizumab.Approved, Vet Approved
PilocarpineThe serum concentration of Pilocarpine can be decreased when it is combined with Tocilizumab.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tocilizumab.Approved, Investigational
PimozideThe serum concentration of Pimozide can be decreased when it is combined with Tocilizumab.Approved
PinacidilThe serum concentration of Pinacidil can be decreased when it is combined with Tocilizumab.Withdrawn
PioglitazoneThe serum concentration of Pioglitazone can be decreased when it is combined with Tocilizumab.Approved, Investigational
PipotiazineThe serum concentration of Pipotiazine can be decreased when it is combined with Tocilizumab.Approved
PirfenidoneTocilizumab may increase the immunosuppressive activities of Pirfenidone.Investigational
PodofiloxThe serum concentration of Podofilox can be decreased when it is combined with Tocilizumab.Approved
PomalidomideThe serum concentration of Pomalidomide can be decreased when it is combined with Tocilizumab.Approved
PonatinibThe serum concentration of Ponatinib can be decreased when it is combined with Tocilizumab.Approved
PosaconazoleThe serum concentration of Posaconazole can be decreased when it is combined with Tocilizumab.Approved, Investigational, Vet Approved
PrasteroneThe serum concentration of Prasterone can be decreased when it is combined with Tocilizumab.Approved, Nutraceutical
PrasugrelThe serum concentration of Prasugrel can be decreased when it is combined with Tocilizumab.Approved
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Tocilizumab.Approved
PrazepamThe serum concentration of Prazepam can be decreased when it is combined with Tocilizumab.Approved, Illicit
PraziquantelThe serum concentration of Praziquantel can be decreased when it is combined with Tocilizumab.Approved, Vet Approved
PrednisoloneThe serum concentration of Prednisolone can be decreased when it is combined with Tocilizumab.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be decreased when it is combined with Tocilizumab.Approved, Vet Approved
PrimaquineThe serum concentration of Primaquine can be decreased when it is combined with Tocilizumab.Approved
ProchlorperazineThe serum concentration of Prochlorperazine can be decreased when it is combined with Tocilizumab.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be decreased when it is combined with Tocilizumab.Approved, Vet Approved
ProguanilThe serum concentration of Proguanil can be decreased when it is combined with Tocilizumab.Approved
PromazineThe serum concentration of Promazine can be decreased when it is combined with Tocilizumab.Approved, Vet Approved
PropafenoneThe serum concentration of Propafenone can be decreased when it is combined with Tocilizumab.Approved
PropofolThe serum concentration of Propofol can be decreased when it is combined with Tocilizumab.Approved, Investigational, Vet Approved
PropranololThe serum concentration of Propranolol can be decreased when it is combined with Tocilizumab.Approved, Investigational
PyrazinamideThe serum concentration of Pyrazinamide can be decreased when it is combined with Tocilizumab.Approved
QuazepamThe serum concentration of Quazepam can be decreased when it is combined with Tocilizumab.Approved, Illicit
QuetiapineThe serum concentration of Quetiapine can be decreased when it is combined with Tocilizumab.Approved
QuinacrineThe serum concentration of Quinacrine can be decreased when it is combined with Tocilizumab.Approved
QuinidineThe serum concentration of Quinidine can be decreased when it is combined with Tocilizumab.Approved
QuinineThe serum concentration of Quinine can be decreased when it is combined with Tocilizumab.Approved
RabeprazoleThe serum concentration of Rabeprazole can be decreased when it is combined with Tocilizumab.Approved, Investigational
Rabies vaccineThe risk or severity of adverse effects can be increased when Tocilizumab is combined with Rabies vaccine.Approved
Rabies vaccineThe therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Tocilizumab.Approved
RaloxifeneThe serum concentration of Raloxifene can be decreased when it is combined with Tocilizumab.Approved, Investigational
RamelteonThe serum concentration of Ramelteon can be decreased when it is combined with Tocilizumab.Approved, Investigational
RanolazineThe serum concentration of Ranolazine can be decreased when it is combined with Tocilizumab.Approved, Investigational
ReboxetineThe serum concentration of Reboxetine can be decreased when it is combined with Tocilizumab.Approved, Investigational
RegorafenibThe serum concentration of Regorafenib can be decreased when it is combined with Tocilizumab.Approved
RepaglinideThe serum concentration of Repaglinide can be decreased when it is combined with Tocilizumab.Approved, Investigational
RetapamulinThe serum concentration of Retapamulin can be decreased when it is combined with Tocilizumab.Approved
RifabutinThe serum concentration of Rifabutin can be decreased when it is combined with Tocilizumab.Approved
RifampicinThe serum concentration of Rifampicin can be decreased when it is combined with Tocilizumab.Approved
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Tocilizumab.Approved
RimonabantThe serum concentration of Rimonabant can be decreased when it is combined with Tocilizumab.Approved, Investigational
RiociguatThe serum concentration of Riociguat can be decreased when it is combined with Tocilizumab.Approved
RisperidoneThe serum concentration of Risperidone can be decreased when it is combined with Tocilizumab.Approved, Investigational
RitonavirThe serum concentration of Ritonavir can be decreased when it is combined with Tocilizumab.Approved, Investigational
RituximabThe risk or severity of adverse effects can be increased when Rituximab is combined with Tocilizumab.Approved
RivaroxabanThe serum concentration of Rivaroxaban can be decreased when it is combined with Tocilizumab.Approved
RofecoxibThe serum concentration of Rofecoxib can be decreased when it is combined with Tocilizumab.Investigational, Withdrawn
RoflumilastRoflumilast may increase the immunosuppressive activities of Tocilizumab.Approved
RolapitantThe serum concentration of Rolapitant can be decreased when it is combined with Tocilizumab.Approved
RomidepsinThe serum concentration of Romidepsin can be decreased when it is combined with Tocilizumab.Approved, Investigational
RopiniroleThe serum concentration of Ropinirole can be decreased when it is combined with Tocilizumab.Approved, Investigational
RopivacaineThe serum concentration of Ropivacaine can be decreased when it is combined with Tocilizumab.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be decreased when it is combined with Tocilizumab.Approved
RotigotineThe serum concentration of Rotigotine can be decreased when it is combined with Tocilizumab.Approved
RoxithromycinThe serum concentration of Roxithromycin can be decreased when it is combined with Tocilizumab.Approved, Withdrawn
RuxolitinibThe serum concentration of Ruxolitinib can be decreased when it is combined with Tocilizumab.Approved
SalmeterolThe serum concentration of Salmeterol can be decreased when it is combined with Tocilizumab.Approved
SaquinavirThe serum concentration of Saquinavir can be decreased when it is combined with Tocilizumab.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Tocilizumab.Approved
SelegilineThe serum concentration of Selegiline can be decreased when it is combined with Tocilizumab.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be decreased when it is combined with Tocilizumab.Approved
SeratrodastThe serum concentration of Seratrodast can be decreased when it is combined with Tocilizumab.Approved, Investigational
SertindoleThe serum concentration of Sertindole can be decreased when it is combined with Tocilizumab.Approved, Withdrawn
SertralineThe serum concentration of Sertraline can be decreased when it is combined with Tocilizumab.Approved
SevofluraneThe serum concentration of Sevoflurane can be decreased when it is combined with Tocilizumab.Approved, Vet Approved
SibutramineThe serum concentration of Sibutramine can be decreased when it is combined with Tocilizumab.Approved, Illicit, Investigational, Withdrawn
SildenafilThe serum concentration of Sildenafil can be decreased when it is combined with Tocilizumab.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be decreased when it is combined with Tocilizumab.Approved
SimeprevirThe serum concentration of Simeprevir can be decreased when it is combined with Tocilizumab.Approved
SimvastatinThe serum concentration of Simvastatin can be decreased when it is combined with Tocilizumab.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Tocilizumab.Approved
SirolimusThe serum concentration of Sirolimus can be decreased when it is combined with Tocilizumab.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be decreased when it is combined with Tocilizumab.Approved, Investigational
SolifenacinThe serum concentration of Solifenacin can be decreased when it is combined with Tocilizumab.Approved
SonidegibThe serum concentration of Sonidegib can be decreased when it is combined with Tocilizumab.Approved, Investigational
SorafenibThe serum concentration of Sorafenib can be decreased when it is combined with Tocilizumab.Approved, Investigational
SpiramycinThe serum concentration of Spiramycin can be decreased when it is combined with Tocilizumab.Approved
SRP 299The risk or severity of adverse effects can be increased when Tocilizumab is combined with SRP 299.Investigational
SufentanilThe serum concentration of Sufentanil can be decreased when it is combined with Tocilizumab.Approved, Investigational
SulfadiazineThe serum concentration of Sulfadiazine can be decreased when it is combined with Tocilizumab.Approved, Vet Approved
SulfamethoxazoleThe serum concentration of Sulfamethoxazole can be decreased when it is combined with Tocilizumab.Approved
SulfinpyrazoneThe serum concentration of Sulfinpyrazone can be decreased when it is combined with Tocilizumab.Approved
SunitinibThe serum concentration of Sunitinib can be decreased when it is combined with Tocilizumab.Approved, Investigational
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Tocilizumab.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Synthetic Conjugated Estrogens, B can be decreased when it is combined with Tocilizumab.Approved
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Tocilizumab.Approved, Investigational
TacrolimusThe serum concentration of Tacrolimus can be decreased when it is combined with Tocilizumab.Approved, Investigational
TadalafilThe serum concentration of Tadalafil can be decreased when it is combined with Tocilizumab.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be decreased when it is combined with Tocilizumab.Approved
TamsulosinThe serum concentration of Tamsulosin can be decreased when it is combined with Tocilizumab.Approved, Investigational
TasosartanThe serum concentration of Tasosartan can be decreased when it is combined with Tocilizumab.Approved
Taurochenodeoxycholic acidThe serum concentration of Taurochenodeoxycholic acid can be decreased when it is combined with Tocilizumab.Experimental
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Tocilizumab.Approved
TelithromycinThe serum concentration of Telithromycin can be decreased when it is combined with Tocilizumab.Approved
TemazepamThe serum concentration of Temazepam can be decreased when it is combined with Tocilizumab.Approved
TemsirolimusThe serum concentration of Temsirolimus can be decreased when it is combined with Tocilizumab.Approved
TeniposideThe serum concentration of Teniposide can be decreased when it is combined with Tocilizumab.Approved
TerbinafineThe serum concentration of Terbinafine can be decreased when it is combined with Tocilizumab.Approved, Investigational, Vet Approved
TerfenadineThe serum concentration of Terfenadine can be decreased when it is combined with Tocilizumab.Withdrawn
TesmilifeneThe serum concentration of Tesmilifene can be decreased when it is combined with Tocilizumab.Investigational
TestosteroneThe serum concentration of Testosterone can be decreased when it is combined with Tocilizumab.Approved, Investigational
TetracyclineThe serum concentration of Tetracycline can be decreased when it is combined with Tocilizumab.Approved, Vet Approved
TG4010The risk or severity of adverse effects can be increased when Tocilizumab is combined with TG4010.Investigational
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Tocilizumab.Approved
ThiotepaThe serum concentration of Thiotepa can be decreased when it is combined with Tocilizumab.Approved
TiagabineThe serum concentration of Tiagabine can be decreased when it is combined with Tocilizumab.Approved
TicagrelorThe serum concentration of Ticagrelor can be decreased when it is combined with Tocilizumab.Approved
TiclopidineThe serum concentration of Ticlopidine can be decreased when it is combined with Tocilizumab.Approved
TinidazoleThe serum concentration of Tinidazole can be decreased when it is combined with Tocilizumab.Approved, Investigational
TiotropiumThe serum concentration of Tiotropium can be decreased when it is combined with Tocilizumab.Approved
TipranavirThe serum concentration of Tipranavir can be decreased when it is combined with Tocilizumab.Approved, Investigational
TofacitinibThe risk or severity of adverse effects can be increased when Tocilizumab is combined with Tofacitinib.Approved, Investigational
TolterodineThe serum concentration of Tolterodine can be decreased when it is combined with Tocilizumab.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be decreased when it is combined with Tocilizumab.Approved
ToremifeneThe serum concentration of Toremifene can be decreased when it is combined with Tocilizumab.Approved, Investigational
TrabectedinThe serum concentration of Trabectedin can be decreased when it is combined with Tocilizumab.Approved, Investigational
TramadolThe serum concentration of Tramadol can be decreased when it is combined with Tocilizumab.Approved, Investigational
TrastuzumabTrastuzumab may increase the neutropenic activities of Tocilizumab.Approved, Investigational
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be decreased when it is combined with Tocilizumab.Approved
TrazodoneThe serum concentration of Trazodone can be decreased when it is combined with Tocilizumab.Approved, Investigational
TretinoinThe serum concentration of Tretinoin can be decreased when it is combined with Tocilizumab.Approved, Investigational, Nutraceutical
TriamcinoloneThe serum concentration of Triamcinolone can be decreased when it is combined with Tocilizumab.Approved, Vet Approved
TriazolamThe serum concentration of Triazolam can be decreased when it is combined with Tocilizumab.Approved
TrimethadioneThe serum concentration of Trimethadione can be decreased when it is combined with Tocilizumab.Approved
TrimethoprimThe serum concentration of Trimethoprim can be decreased when it is combined with Tocilizumab.Approved, Vet Approved
TrimipramineThe serum concentration of Trimipramine can be decreased when it is combined with Tocilizumab.Approved
TroglitazoneThe serum concentration of Troglitazone can be decreased when it is combined with Tocilizumab.Withdrawn
TroleandomycinThe serum concentration of Troleandomycin can be decreased when it is combined with Tocilizumab.Approved
UdenafilThe serum concentration of Udenafil can be decreased when it is combined with Tocilizumab.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Tocilizumab.Approved
ValdecoxibThe serum concentration of Valdecoxib can be decreased when it is combined with Tocilizumab.Investigational, Withdrawn
VandetanibThe serum concentration of Vandetanib can be decreased when it is combined with Tocilizumab.Approved
VanoxerineThe serum concentration of Vanoxerine can be decreased when it is combined with Tocilizumab.Investigational
VardenafilThe serum concentration of Vardenafil can be decreased when it is combined with Tocilizumab.Approved
VemurafenibThe serum concentration of Vemurafenib can be decreased when it is combined with Tocilizumab.Approved
VenetoclaxThe serum concentration of Venetoclax can be decreased when it is combined with Tocilizumab.Approved
VenlafaxineThe serum concentration of Venlafaxine can be decreased when it is combined with Tocilizumab.Approved
VerapamilThe serum concentration of Verapamil can be decreased when it is combined with Tocilizumab.Approved
VicrivirocThe serum concentration of Vicriviroc can be decreased when it is combined with Tocilizumab.Investigational
VilanterolThe serum concentration of Vilanterol can be decreased when it is combined with Tocilizumab.Approved
VilazodoneThe serum concentration of Vilazodone can be decreased when it is combined with Tocilizumab.Approved
VinblastineThe serum concentration of Vinblastine can be decreased when it is combined with Tocilizumab.Approved
VincristineThe serum concentration of Vincristine can be decreased when it is combined with Tocilizumab.Approved, Investigational
VindesineThe serum concentration of Vindesine can be decreased when it is combined with Tocilizumab.Approved
VinorelbineThe serum concentration of Vinorelbine can be decreased when it is combined with Tocilizumab.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be decreased when it is combined with Tocilizumab.Approved
VoriconazoleThe serum concentration of Voriconazole can be decreased when it is combined with Tocilizumab.Approved, Investigational
VortioxetineThe serum concentration of Vortioxetine can be decreased when it is combined with Tocilizumab.Approved
WarfarinThe serum concentration of Warfarin can be decreased when it is combined with Tocilizumab.Approved
YohimbineThe serum concentration of Yohimbine can be decreased when it is combined with Tocilizumab.Approved, Vet Approved
ZafirlukastThe serum concentration of Zafirlukast can be decreased when it is combined with Tocilizumab.Approved, Investigational
ZalcitabineThe serum concentration of Zalcitabine can be decreased when it is combined with Tocilizumab.Approved
ZaleplonThe serum concentration of Zaleplon can be decreased when it is combined with Tocilizumab.Approved, Illicit, Investigational
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Tocilizumab.Approved
ZileutonThe serum concentration of Zileuton can be decreased when it is combined with Tocilizumab.Approved, Investigational, Withdrawn
ZiprasidoneThe serum concentration of Ziprasidone can be decreased when it is combined with Tocilizumab.Approved
ZolpidemThe serum concentration of Zolpidem can be decreased when it is combined with Tocilizumab.Approved
ZomepiracThe serum concentration of Zomepirac can be decreased when it is combined with Tocilizumab.Withdrawn
ZonisamideThe serum concentration of Zonisamide can be decreased when it is combined with Tocilizumab.Approved, Investigational
ZopicloneThe serum concentration of Zopiclone can be decreased when it is combined with Tocilizumab.Approved
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Mihara M, Nishimoto N, Ohsugi Y: The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody. Expert Opin Biol Ther. 2005 May;5(5):683-90. [PubMed:15934843 ]
External Links
ATC CodesL04AC07
AHFS Codes
  • 92:36
PDB EntriesNot Available
FDA labelDownload (623 KB)
MSDSDownload (482 KB)
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Injection, solutionSubcutaneous180 mg/mL
Injection, solution, concentrateIntravenous20 mg/mL
SolutionIntravenous200 mg
SolutionIntravenous400 mg
SolutionIntravenous80 mg
SolutionSubcutaneous162 mg
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1341152 No2000-12-122017-12-12Canada
CA2201781 No2010-01-122015-06-07Canada
Properties
StateLiquid
Experimental PropertiesNot Available
Taxonomy
DescriptionNot Available
KingdomOrganic Compounds
Super ClassOrganic Acids
ClassCarboxylic Acids and Derivatives
Sub ClassAmino Acids, Peptides, and Analogues
Direct ParentPeptides
Alternative ParentsNot Available
SubstituentsNot Available
Molecular FrameworkNot Available
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antibody
General Function:
Protein homodimerization activity
Specific Function:
Part of the receptor for interleukin 6. Binds to IL6 with low affinity, but does not transduce a signal. Signal activation necessitate an association with IL6ST. Activation may lead to the regulation of the immune response, acute-phase reactions and hematopoiesis.Low concentration of a soluble form of IL6 receptor acts as an agonist of IL6 activity.
Gene Name:
IL6R
Uniprot ID:
P08887
Molecular Weight:
51547.015 Da
References
  1. Smolen JS, Maini RN: Interleukin-6: a new therapeutic target. Arthritis Res Ther. 2006;8 Suppl 2:S5. Epub 2006 Jul 28. [PubMed:16899109 ]
Comments
comments powered by Disqus
Drug created on March 19, 2008 10:20 / Updated on August 17, 2016 12:24